Common Contracts

Contract

BriaCell Therapeutics Corp. • May 17th, 2024 • Pharmaceutical preparations • New York

• Company
  BriaCell Therapeutics Corp.
• Filed
  May 17th, 2024
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (the “Placement Agent”), as sole placement agent, and BriaCell Therapeutics Corp., a British Colombia corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered securities of the Company, consisting of: (i) common shares, no par value (“Common Shares”), (ii) pre-funded warrants to purchase Common Shares (the “Pre-Funded Warrants”) and (iii) warrants to purchase Common Shares (the “Common Warrants,” and together with the Pre-Funded Warrants, the “Warrants”). The Common Shares and Warrants actually sold by the Placement Agent are referred to herein as the “Placement Agent Securities.” The Placement Agent Securities and Common Shares issuable upon the exercise of the Warrants shall be offere

Contract

Banzai International, Inc. • May 16th, 2024 • Services-prepackaged software • New York

• Company
  Banzai International, Inc.
• Filed
  May 16th, 2024
• Industry
  Services-prepackaged software
• Jurisdiction
  New York

Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Agent”), and Banzai International, Inc., a Delaware corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered securities of the Company, consisting of: (i) shares of Class A common stock, par value $0.0001 per share (“Common Stock”), (ii) pre-funded warrants to purchase Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase Common Stock (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants”). The Common Stock and Warrants actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The Placement Agent Securities

Contract

T2 Biosystems, Inc. • May 6th, 2024 • Surgical & medical instruments & apparatus • New York

• Company
  T2 Biosystems, Inc.
• Filed
  May 6th, 2024
• Industry
  Surgical & medical instruments & apparatus
• Jurisdiction
  New York

Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (the “Placement Agent”), as sole placement agent, and T2 Biosystems, Inc., a Delaware corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed offering (the “Placement”) of securities of the Company, consisting of: (i) shares of common stock, par value $0.001 per share (“Common Stock”), (ii) pre-funded warrants to purchase shares of Common Stock (the “Pre-Funded Warrants”), (iii) Series B-1 warrants to purchase shares of Common Stock (the “Series B-1 Warrants”) and (iv) Series B-2 warrants to purchase shares of Common Stock (the “Series B-2 Warrants” and collectively with the Pre-Funded Warrants and the Series B-1 Warrants, the “Warrants”). The Common Stock and Warrants actually sold by the Placement Agent are referred to herei